MedTrace Logo

Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain

NCT02262676 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2251

Last updated 2017-01-23

No results posted yet for this study

Summary

Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice

Conditions

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Patients treated by Physicians under approved local prescriptions

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-02-28
Completion
2015-05-31

Countries

  • Spain

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02262676 on ClinicalTrials.gov